CAMBRIDGE, Mass., July 9, 2019 /PRNewswire/ -- GNS Healthcare
(GNS), a leading precision medicine company, today announced a
$23 million Series D fundraising
round, led by Cigna Ventures, a strategic corporate venture capital
partner and wholly owned indirect subsidiary of Cigna Corporation
(NYSE: CI). Joining the Cigna Ventures-led funding round were
Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture
Investments, as well as former Caesar's CEO and Aetna Division
President Gary Loveman.
"We are thrilled to have Cigna contribute to our next phase of
growth," said Colin Hill, Chairman,
CEO and Co-Founder of GNS Healthcare. "As one of the largest
and most forward-thinking global health services companies, Cigna
is the perfect complement to our cadre of leading biopharma
companies and health plan partners committed to improving patient
outcomes through causal AI and the precision healthcare it
enables."
As a pioneer in machine learning and its application to
healthcare, GNS brings an unparalleled depth and breadth of
experience in leveraging artificial intelligence to solve
healthcare's most crucial problems. GNS's causal AI technology
transforms data streams into in silico patients that
precisely match therapeutics, procedures and care management
interventions to individuals to drive personalized clinical care
and medicine and improve health outcomes. The latest funding round
will enable Cigna and others to deliver on increasing consumer
demand for personalization in new and more effective ways.
"Cigna is committed to improving the total health and well-being
of our customers – and the personalized clinical care interventions
that we expect GNS to facilitate will play a huge role in achieving
those improvements," said Tom
Richards, Global Lead, Strategy & Business Development
at Cigna. "GNS aligns with our vision and together we can
super-charge our advanced analytics capabilities and provide even
deeper, more predictable insights that will further enhance
customer access to the highest quality treatment and care, in the
preferred and appropriate place, at the right time."
With this announcement, Cigna joins other leading carriers and
health plans and GNS investors, including Cambia Health Solutions,
Echo Health Ventures, Horizon Blue Cross of NJ and Heritage
Provider Network, as well as leading biopharma companies, including
Amgen Ventures, Celgene Corporation and Zambon Pharmaceuticals, and
other investors Mitsui, GHO Capital, Alexandria Venture
Investments, Fort Rock Capital and Gary
Loveman.
About GNS Healthcare
GNS Healthcare solves
healthcare's matching problem for leading health plans, biopharma
companies, and health systems. GNS transforms massive and diverse
data streams to precisely match therapeutics, procedures, and care
management interventions to individuals, improving health outcomes
and saving billions of dollars. The GNS causal learning and
simulation platform, REFS, accelerates the discovery of what works
for whom and why. www.gnshealthcare.com
About REFS™
REFS™ (Reverse Engineering & Forward
Simulation) is GNS Healthcare's patented causal learning and
simulation platform. Unlike traditional artificial intelligence
platforms, REFS analyzes data sets beyond correlation, instead
inferring causal mechanisms between variables to answer questions
such as: How will the patient respond to this treatment? What if we
choose one intervention over another? REFS is the only
commercially available platform that infers causal mechanisms from
patient data at scale from traditional healthcare and emerging data
sources to bring the promise of precision medicine within
reach.
About Cigna Ventures
Cigna Ventures is a venture
capital fund that works closely with entrepreneurs across the
health care ecosystem to accelerate growth and innovation through
the strategic use of capital and deep partnerships. Cigna Ventures
is a wholly owned indirect subsidiary of Cigna Corporation (NYSE:
CI). To learn more about Cigna Ventures visit:
www.cignaventures.com
About Cigna
Cigna Corporation (NYSE: CI) is a global
health service company dedicated to improving the health,
well-being and peace of mind of those we serve. Cigna delivers
choice, predictability, affordability and access to quality care
through integrated capabilities and connected, personalized
solutions that advance whole person health. All products and
services are provided exclusively by or through operating
subsidiaries of Cigna Corporation, including Cigna Health and Life
Insurance Company, Connecticut General Life Insurance Company, Life
Insurance Company of North
America, Cigna Life Insurance Company of New York, Express Scripts companies or their
affiliates. Such products and services include an integrated suite
of health services, such as medical, dental, behavioral health,
pharmacy, vision, supplemental benefits, and other related products
including group life, accident and disability insurance.
Cigna maintains sales capability in over 30 countries and
jurisdictions and has more than 165 million customer relationships
throughout the world. To learn more about Cigna®,
including links to follow us on Facebook or Twitter, visit
www.cigna.com.
GNS Media Contact:
Patty Kellicker
VP, Marketing
pkellicker@gnshealthcare.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/gns-healthcare-raises-23-million-led-by-cigna-ventures-300880934.html
SOURCE GNS Healthcare